__timestamp | Eli Lilly and Company | Novo Nordisk A/S |
---|---|---|
Tuesday, January 1, 2019 | 122369084370 | 915808743862.0308 |
Wednesday, January 1, 2020 | 153244924560 | 992801077492.3201 |
Friday, January 1, 2021 | 250521319860.00003 | 1681508787391.9998 |
Saturday, January 1, 2022 | 329891098240 | 2129286754102.3198 |
Sunday, January 1, 2023 | 526678270123.72 | 3139248089387.3394 |
Unleashing the power of data
In the past five years, the pharmaceutical titans Eli Lilly and Novo Nordisk have showcased remarkable growth in market capitalization. As of 2023, Novo Nordisk's market cap surged by an impressive 243% from its 2019 value, reaching a staggering 3.1 trillion. Meanwhile, Eli Lilly experienced a robust 330% increase, climbing to 527 billion. This growth reflects the companies' strategic innovations and expanding influence in the global healthcare sector.
Novo Nordisk, renowned for its diabetes care solutions, has consistently outpaced Eli Lilly in market cap, maintaining a lead of over 500% in 2023. However, Eli Lilly's rapid ascent, particularly in the last two years, underscores its aggressive expansion and diversification strategies. As these industry leaders continue to innovate, their market trajectories offer valuable insights into the evolving landscape of global pharmaceuticals.
5 Year Trend in Average Market Capitalization for AbbVie
Annual Comparison of SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline
Average Market Capitalization of Abbvie Annually
Comparison of R&D Expenses for Pfizer and AstraZeneca in 2023
Comparison of Average SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline Over the Years
Comparison of Average SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline Over the Years
Number of Employees for Top 10 Pharma Companies
5 Year Trend in Average Market Capitalization for AbbVie
5 Year Trend in Market Capitalization for AbbVie
Comparison of R&D Expenses for Pfizer and AstraZeneca in 2023
Number of Employees for Top 10 Healthcare Companies
Comparison of Net Income Margin for Glaxosmithkline, AstraZeneca, Takeda, and Eli Lilly Over the Last 8 Quarters